Premier Partners led a $15m round in Celltrio.

Premier Partners, an investor in healthcare innovation, led a $15m round in Celltrio, a life sciences company delivering advanced automation solutions for cell culturing and cell and gene therapy. "We are highly impressed by Celltrio’s customer traction and its differentiated intellectual property in cell culturing and cell & gene therapy automation. We believe Celltrio is poised to become a category-defining leader, delivering scalable, sterile automation to laboratories and manufacturing facilities worldwide," Jay Song, Premier Partners CEO.